By Pharmatest Services…
To get in touch with Pharmatest launching new cancer products at AACR San Diego, simply fill out the form below.
Subscribe to Supplier
Pharmatest launching new cancer products at AACR San Diego
Turku, Finland: – Oncology and skeletal disease specialist CRO Pharmatest will use its appearance at next month’s Annual Meeting of American Association for Cancer Research (AACR) conference to launch several new service products targeted on human cancers.
The four-day AACR 2014 meeting opens in San Diego, California, on April 5.
Pharmatest will be present as an exhibitor (Booth 848) and will also contribute to the conference agenda. The Finnish-based CRO will make three scientific presentations that demonstrate efficacy of customer compounds for cancer treatment.
The new compounds were developed during studies performed in collaboration with Bayer Pharma AG, Exelixis, Inc. and Virobay, Inc.. All three companies have credited the high quality of Pharmatest and its services.
Pharmatest’s new cancer products include robotics-based in vitro high throughput screening and patient-derived xenograft models. Pharmatest will publish more detailed newsletters about the new models before the AACR meeting and make them available to customers as service products after the event.
Jussi Halleen, CEO of Pharmatest said: “We are happy to be back at AACR. Once again, we will be able to present the meeting with exciting new data and models.”
“I am very proud of these new models that complement our existing products and help us to serve our customers with an even wider range of services over the coming years,” added Mr. Halleen.
Pharmatest Services Ltd (Pharmatest) is a contract research organisation (CRO) specializing in clinically predictive preclinical efficacy services in the therapeutic areas of oncology and skeletal diseases.
Pharmatest helps establish proof-of-efficacy of cancer drug candidates with cell culture assays, organotypic 3D models, orthotopic animal models, and disseminated cancer models. Its models of skeletal diseases include bone cell culture assays and animal models of osteoporosis and osteoarthritis that can also be used for bone safety testing.
Headquartered in Turku, Finland, Pharmatest’s preclinical research unit offers modern research facilities including fully equipped laboratories and barrier-type animal facilities.
The CRO has supported close to 100 clients from pharmaceutical and biotechnology organizations worldwide in research to develop new therapeutics against cancer and skeletal diseases. It has also assisted many nutraceutical companies in the development of new phytopharmaceutical products.
Pharmatest has developed a proven ability to reduce costs and notably increase the speed of drug development by processing outsourced preclinical efficacy testing with maximum efficiency and providing clients with access to latest translational tools for lead validation and proof-of-concept studies in oncology and skeletal diseases.
About AACR 2014
The Annual Meeting of the American Association for Cancer Research is one of the world’s largest and most prestigious life sciences events. AACR 2014 will be held at the San Diego Convention Center in California, from April 5-9. The exhibition (open April 6-9) features more than 350 companies and organizations representing a wide array of products and services in laboratory and clinical research.
The 2013 AACR Annual Meeting, held in Washington DC, attracted more than 18,000 visitors and delegates from around the world.
Jussi Halleen; CEO, Pharmatest Services Ltd.
Tel.: + 358 50 380 9551
Andrew Heiniluoma US Sales Representative, Pharmatest
Tel: +1 978 340 1028
Click on Pharmatest launching new cancer products at AACR San Diego for other information.
Click on Pharmatest to contact the company directly.